Healthcare Innovations Venture Investment Forum
December 6 – 8, 2017
Please join us for Wilson Sonsini Goodrich & Rosati’s Healthcare Innovations Venture Investment Forum.
Companies selected for a meeting with an investor(s) during the forum will have the opportunity to privately meet with the investor for about 40 minutes. Participating companies are expected to have flexible availability on each of the program dates.
How to Participate:
1. Submit your company information using the form below
2. Email your executive summary* and non-confidential deck
*Executive summaries should be a 1-2 page PDF document, and include (a) a summary of your technology and the business opportunity; and (b) a listing of your executive management team and their experience.
Deadline for submitting executive summaries for consideration is September 15th.
Companies will be notified whether or not they have been selected to participate beginning on November 6.
Confirmed Investors Meeting Companies in Person:
3M Ventures, 5AM Ventures, AbbVie Biotech Ventures, Apple Tree Partners, Atlas Venture, ARCH Venture Partners, Bain Capital, Bay City Capital, Deerfield, Gurnet Point Capital, HIG Capital, Illumina Ventures, J&J Innovations, Lilly Ventures, Merck Global Health Innovation Fund, NEA, Novartis Institutes for Biomedical Research, Novo Ventures, Pfizer, Inc., RA Capital, Sailing Capital, Siemens Healthineers, SR One, Taiho Ventures, 8VC, Accelerator Corp., Ajax Health, Apex Landmark, Cartmell VC, Charles River Ventures, Civilization Ventures, Hatteras Venture Partners, Integra LifeSciences Holdings, KdT Ventures, Live Oak Venture Partners, Mercury Fund, MP Healthcare Venture Management, PTV Healthcare, S3 Ventures, Santé Ventures, Thiel Capital, Translink Capital Partners, and True Wealth Ventures.
Additionally, these companies will review submissions separately: Asahi Kasei Ventures, Avalon Ventures, Emergent Medical Partners, Foresite Capital, Fortress Biotech, Founders Fund, F-Prime Capital Partners, Frazier Healthcare Partners, GE Ventures, OrbiMed, Pivotal bioVenture Partners, Section 32, TPG Biotech, and Versant Ventures.